Biom Completes safety and efficacy data of BIO017 in preclinical Angelman Syndrome mouse model. Biom Therapeutics’ Open label clinical study show preliminary efficacy data of BIO017 in epileptic patients
Biom Therapeutics files for orphan disease designation for lead candidate BIO017. Biom Therapeutics meeting with FDA for pre-IND meeting
Biom Therapeutics partnered with Canopy Growth. Biom Therapeutics partnered with Alchem for clinical drug manufacturing for pivotal study
Biom Therapeutics invited for Biopitch in Annual BioFlorida Annual Event. Biom Therapeutics in final three companies presenting in BioPitch in Annual BioFlorida Annual Event
Dr. Thomas Patton joins the Biom Therapeutics as Chief Medical Officer
Biom Therapeutics selected as a finalist at BioFlorida annual Biopitch competition for early-stage life science companies Biom Therapeutics receives prestigious recognition at BioFlorida annual conference. SARASOTA, Fl. Nov. ...